Viridian Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 24.8 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.81B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves’ disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
Details
| Name | Viridian Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 252 |
| Founded | 2006 |
| Ceo | Stephen Mahoney |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US92790C1045 |
| Cusip | 92790C104 |
| Cik | 1590750 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Stephen F. Mahoney J.D., MBA | Chief Executive Officer, President and Director |
| Seth Harmon | Chief Financial Officer |
| Thomas W. Beetham J.D., MBA | Chief Operating Officer |
| Jennifer Tousignant J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Radhika Tripuraneni M.D., M.P.H. | Chief Medical Officer |
| Dr. Eric N. Olson Ph.D. | Co-Founder and Chairman of Scientific Advisory Board |
| Dr. Michael R. Bristow M.D., Ph.D. | Co-Founder and Member of the Scientific Advisory Board |
| Dr. Marvin H. Caruthers Ph.D. | Co-Founder and Scientific Advisory Board Member |
| Vahe Bedian Ph.D. | Co-Founder and Scientific Advisor |
| Melissa Manno | Chief Human Resources Officer |
Contact
| Address | 221 Crescent Street, Suite 103A, Waltham, Massachusetts 02453, United States |
| Phone | 617 272 4600 |
| Website | https://www.viridiantherapeutics.com |